These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 34197272)

  • 1. Safety of Sars-Cov-2 vaccines administration for adult patients with hereditary fructose intolerance.
    Urru SAM; Maines E; Campomori A; Soffiati M
    Hum Vaccin Immunother; 2021 Nov; 17(11):4112-4114. PubMed ID: 34197272
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply letter to "safety of SARS-Cov-2 vaccines administration for adult patients with hereditary fructose intolerance".
    Saborido-Fiaño R; Martinón-Torres N; Crujeiras-Martinez V; Couce ML; Leis R
    Hum Vaccin Immunother; 2021 Nov; 17(11):4115-4116. PubMed ID: 34473597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reply letter to the editor concerning the article 'Safety of Sars-Cov-2 vaccines administration for adult patients with hereditary fructose intolerance'.
    Izquierdo-Garcia E; Alvaro Alonso EA; Montero Pastor B; Such Díaz A; Escobar Rodríguez I
    Hum Vaccin Immunother; 2022 Nov; 18(5):2051414. PubMed ID: 35358012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of vaccines administration in hereditary fructose intolerance.
    Maiorana A; Sabia A; Corsetti T; Dionisi-Vici C
    Orphanet J Rare Dis; 2020 Oct; 15(1):274. PubMed ID: 33004052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Letter to the editor concerning the article 'Safety of vaccines administration in hereditary fructose intolerance'.
    Saborido-Fiaño R; Martinón-Torres N; Crujeiras-Martinez V; Couce ML; Leis R
    Hum Vaccin Immunother; 2021 Aug; 17(8):2593-2594. PubMed ID: 33653220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
    Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.
    Lim HX; Arip M; Yahaya AAA; Jazayeri SD; Poppema S; Poh CL
    Front Biosci (Landmark Ed); 2021 Nov; 26(11):1286-1304. PubMed ID: 34856768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 vaccines: a triumph of science and collaboration.
    Golob JL; Lugogo N; Lauring AS; Lok AS
    JCI Insight; 2021 May; 6(9):. PubMed ID: 33822773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis.
    Liu Q; Qin C; Liu M; Liu J
    Infect Dis Poverty; 2021 Nov; 10(1):132. PubMed ID: 34776011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson.
    Patel R; Kaki M; Potluri VS; Kahar P; Khanna D
    Hum Vaccin Immunother; 2022 Dec; 18(1):2002083. PubMed ID: 35130825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccine safety - is the SARS-CoV-2 vaccine any different?
    Tau N; Yahav D; Shepshelovich D
    Hum Vaccin Immunother; 2021 May; 17(5):1322-1325. PubMed ID: 33270474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
    Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
    Front Immunol; 2021; 12():726960. PubMed ID: 34671348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Vaccination against SARS-CoV-2 in patients with multiple sclerosis].
    Costa Frossard-França L; García-Domínguez JM; Moreno-Torres I; Fortún J; Villar LM; Meca-Lallana V
    Rev Neurol; 2021 Apr; 72(7):250-260. PubMed ID: 33764494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [SARS-CoV-2 vaccines].
    Benfield TL; Helweg-Larsen J
    Ugeskr Laeger; 2021 Mar; 183(10):. PubMed ID: 33734065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2.
    Jin Y; Hou C; Li Y; Zheng K; Wang C
    Front Immunol; 2021; 12():821538. PubMed ID: 35126377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects.
    Wheeler SE; Shurin GV; Yost M; Anderson A; Pinto L; Wells A; Shurin MR
    Microbiol Spectr; 2021 Sep; 9(1):e0034121. PubMed ID: 34346750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Innate and Adaptive Immune Responses in the Upper Respiratory Tract and the Infectivity of SARS-CoV-2.
    Ramasamy R
    Viruses; 2022 Apr; 14(5):. PubMed ID: 35632675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prior SARS-CoV-2 infection increases reactogenicity after SARS-COV-2 mRNA vaccine and could delay the administration of the vaccine based on timing of infection.
    Stellini R; Gianello R; Meloni A; Croce E; Materzanini P; Gomarasca W
    Infection; 2022 Jun; 50(3):791-793. PubMed ID: 34855188
    [No Abstract]   [Full Text] [Related]  

  • 20. Immune imprinting and SARS-CoV-2 vaccine design.
    Wheatley AK; Fox A; Tan HX; Juno JA; Davenport MP; Subbarao K; Kent SJ
    Trends Immunol; 2021 Nov; 42(11):956-959. PubMed ID: 34580004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.